npg

CORRIGENDA

In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2

Elisabeth Castellanos, Imma Rosas, Ares Solanes, Isabel Bielsa, Conxi Lázaro, Cristina Carrato, Cristina Hostalot, Pepe Prades, Francesc Roca-Ribas, Ignacio Blanco and Eduard Serra on behalf of the NF2 Multidisciplinary Clinics HUGTiP-ICO-IMPPC

European Journal of Human Genetics (2014) 22, 153; doi:10.1038/ejhg.2013.224

Correction to: European Journal of Human Genetics (2013) 21, 769–773; doi:10.1038/ejhg.2012.261; published online 28 November 2012

Post publication the authors realized that they had made some errors in their article for which they would like to apologise. g.74409 T>A the mutation at the genomic level should be termed: g.74408 T>A, and the sequence of the scheme depicted in Figure 1b, contains a couple of single nucleotide changes. A revised figure is shown below.




Figure 1 Deep intronic *NF2* mutation description. (a) Analysis of patient fibroblasts showed a proportion of *NF2* transcripts containing the inclusion of a cryptic exon (NF2 CEI) compared with the WT NF2 mRNA (NF2 WT) (upper panel). Forward sequence of cryptic exon inclusion is shown (bottom panel). (b) Schematic representation of the identified *NF2* deep intronic mutation and MS-PMO location. Constitutive and cryptic exons are represented by dark and light gray boxes, respectively. The boundaries of the cryptic inserted exon are shown in uppercase; flanking intronic sequences are shown in lowercase. MS-PMO sequence is underlined. Mutated nucleotide is shown in bold and the nucleotide change is indicated by an arrow.

Return of whole-genome sequencing results in paediatric research: a statement of the P³G international paediatrics platform

Bartha Maria Knoppers, Denise Avard, Karine Sénécal and Ma'n H Zawati along with the P³G International Paediatrics Platform members

European Journal of Human Genetics (2014) 22, 153-154; doi:10.1038/ejhg.2013.225

Correction to: European Journal of Human Genetics (2014) 22, 3–5; doi:10.1038/ejhg.2013.176; published online 7 August 2013

The authors have added an acknowledgement to their paper since online publication:

This work was supported by grants from the Canadian Institutes of Health Research and the Terry Fox Foundation (TFF-105266), Genome Canada and the Canadian Institutes of Health Research, Finding of Rare Disease Genes in Canada (FORGE), the Maternal Infant and Youth Research Network (MICYRN),